Ask about this productRelated genes to: DKK3 antibody
- Gene:
- DKK3 NIH gene
- Name:
- dickkopf WNT signaling pathway inhibitor 3
- Previous symbol:
- -
- Synonyms:
- REIC, RIG
- Chromosome:
- 11p15.3
- Locus Type:
- gene with protein product
- Date approved:
- 2000-09-01
- Date modifiied:
- 2014-11-19
Related products to: DKK3 antibody
Related articles to: DKK3 antibody
- This study aimed to evaluate the nephrotoxic effects of tramadol (TR) on renal function and the possible protective role of chrysin (CH) based on multiple biochemical, molecular, and metabolic parameters. The administration of TR resulted in substantial elevations in serum creatinine and BUN levels, concurrently increasing renal damage biomarkers including KIM-1, NGAL, FABP, IL-18, MCP-1, and YKL-40. Furthermore, elevated mRNA levels of Cst3, Timp2, Igfbp7, Hgf, IL-9, and Dkk3 were noted, along with a significant increase in inflammation-related proteins IL-1β, IL-3, IL-4, IL-5, IL-6, and IL-21. TR interrupted LINC01187 and additional regulatory RNA networks, reduced the concentrations of β-hydroxybutyrate, NAD, and acetyl-CoA, essential for ketogenesis, and inhibited HMGCS2 expression. Furthermore, reduced levels of Nrf2, PPARγ, XCT, GPX4, and FPN proteins elevated oxidative stress, diminished SOD, CAT, and GPX levels, and heightened MDA concentrations. The CH administration resulted in partial or substantial enhancement in all these parameters, mitigating the molecular, metabolic, and functional decline induced by TR. PCA analysis indicated that CH aligned the biomarker profile more closely with normal physiological levels. These findings indicate that CH may serve as a potential nephroprotective agent in TR-induced renal injury. - Source: PubMed
Publication date: 2026/04/17
Öz Medine AkkanKandemir ÖzgeÖzdemir SelçukŞimşek HasanKüçükler SefaYazıcı RamizMutlu HüseyinKandemir Fatih Mehmet - Following kidney transplantation, rejection, and the presence of interstitial fibrosis and tubular atrophy represents prognostically unfavorable factors and are associated with reduced graft survival. The B-cell activating factor (BAFF) and the profibrotic glycoprotein Dickkopf 3 (DKK3) have been suggested as potential biomarkers and therapeutic targets. In our rat model, we hypothesized that anti-BAFF treatment could not only influence cellular migration patterns but also mediate intragraft fibrosis and modulate DKK3 expression. In an allogeneic setting, kidneys of Brown Norway rats were transplanted into Lewis rats with cyclosporine as standard immunosuppressive therapy (highCNI). To permit chronic rejection and the development of donor-specific antibodies (DSA), some rats received a reduced dosage of cyclosporine A (lowCNI), while another group additionally received a monoclonal anti-BAFF antibody (lowCNI+anti-BAFF) to mitigate immunological activation. The highCNI group exhibited the least immune cell infiltration (CD3/20/68) and lower fibrosis, despite a tendency toward higher DKK3 mRNA levels on day 28. The lowCNI group showed the highest cellular infiltration, accompanied by the most severe fibrosis and a trend toward increased DKK3 expression. In contrast, the lowCNI+anti-BAFF group demonstrated reduced B-cell infiltration, mild fibrosis, and low DKK3 expression. Thus, the results indicate that the addition of anti-BAFF treatment, can eliminate the detrimental effects of under- and over-immunosuppression. - Source: PubMed
Publication date: 2026/04/15
Preiss ADaniel CVonbrunn EScharf MBanas BBergler TSchuster A - Equine melanocytic neoplasms (EMN) are aggressive tumours characterised by high metastatic potential and limited therapeutic options available. However, the molecular mechanisms underlying their progression remain poorly understood. This study therefore presents the integrative phosphoproteomic analysis of EMN tissue, with the aim of elucidating stage-specific alterations in signalling pathways and metabolism. Nineteen tissue samples from grey horses were categorised as normal-stage (n = 6), early-stage EMN (n = 7), and severe-stage EMN (n = 6) and subjected to in-depth analysis using liquid chromatography-tandem mass spectrometry (LC-MS/MS). A total of 2035 phosphoproteins were identified, of which 219 were differentially expressed across the disease stages. Interestingly, early-stage EMN showed dysregulation of inositol phosphate metabolism and activation of the PI3K-Akt pathway which involved INPP5F and PKN2. In severe-stage EMN, upregulation of SYNJ1, STRN4 and VIM indicated enhanced membrane trafficking, cytoskeletal remodelling, and MAPK signalling. Additionally, ASPM and GNAO1 upregulation reflected heightened proliferation and altered Rap1 signalling, while UBR5 dysregulation suggested aberrant protein homeostasis. Metabolic reprogramming was also noticed, with elevated TKT and GAPDH expression supporting glycolysis and NADPH production. Observably, the severe-stage EMN exhibited a higher expression of Dickkopf-3 (DKK3) which suggests a role in aberrant Wnt/β-catenin activation and tumour progression. These findings reveal stage-specific molecular mechanisms in EMN pathogenesis and highlight potential biomarkers and therapeutic targets for equine melanoma. - Source: PubMed
Publication date: 2026/04/16
Srimontri PaitoonKingkaw AmornthepPrapaiwan NawarusSujittosakul RangsimaIamkaewprasert NichapatPiputwat JiraschayaIsama-Al PuettaMunkongdee ThanutchanokChotikaprakal ThanaponYanyongsirikarn PetchpailinPhaonakrop NarumonRoytrakul SittirukVongsangnak WanwipaTesena Parichart - : Gastric cancer (GC) remains a global health challenge, with high mortality rates often linked to late-stage diagnosis. Novel, non-invasive biomarkers are urgently needed to improve the detection and prognosis of this malignant pathology. This study aimed to evaluate the diagnostic and prognostic utility of serum Cluster of Differentiation 276 (CD276) and Dickkopf Related Protein 3 (DKK3) in patients with GC. : In this case-control study, serum levels of CD276 and DKK3 were quantified in 40 GC patients and 40 age-matched healthy controls. The diagnostic performance of each marker and their combination was assessed using Receiver Operating Characteristic (ROC) curve analysis. Correlations between biomarker levels and clinicopathological features were evaluated using Spearman's correlation. The Kaplan-Meier method and the Cox Proportional Hazards Regression Model were used to assess survival. : Serum CD276 levels were found to be significantly elevated in GC patients compared to healthy controls (median 60.06 vs. 18.71 units, < 0.001). Conversely, serum DKK3 levels were significantly suppressed in the GC group (median 92.47 vs. 121.02 units, < 0.001). In ROC analysis, CD276 demonstrated excellent diagnostic accuracy as a standalone biomarker (AUC: 0.836). DKK3 showed independent diagnostic value (AUC: 0.792), but adding DKK3 to CD276 did not provide statistically significant incremental benefit (DeLong's = 0.443). Survival analysis was underpowered due to limited events and short follow-up duration. : In patients with predominantly locally advanced gastric cancer, CD276 can be a primary diagnostic marker, and the addition of DKK3 does not demonstrate a statistically significant improvement but may provide complementary information. Performance in early-stage disease requires validation in future studies. The opposing dysregulation of these markers, reflecting immune checkpoint activation (CD276) and tumor suppressor loss (DKK3), provides a robust and synergistic noninvasive signature. To assess the prognostic value of these two markers, studies involving a larger number of patients and a longer follow-up period are needed. - Source: PubMed
Publication date: 2026/03/12
Fugărețu CosminaȘurlin ValeriuMisarca CatalinCiurea Ana-MariaPatrascu StefanRamboiu Dumitru SanduBoldeanu Mihail VirgilTurcu-Stiolica AdinaLaskou StilianiGrigorescu Cicerone Catalin - Head and neck squamous cell carcinoma (HNSCC) arises from the squamous epithelium of the head and neck region, comprising heterogeneous lesions with distinct risk factors and diverse genetic and epigenetic alteration patterns. HNSCC is often difficult to control when lymph node metastasis has occurred, and treatment outcomes remain unsatisfactory. Elucidating the genetic and epigenetic profiles of cancer-associated genes is essential for improving clinical outcomes, yet to date the key molecules driving HNSCC progression remain unclear. - Source: PubMed
Publication date: 2026/03/07
Katase Naoki